Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Treasury Shares (2021 - 2025)

Historic Treasury Shares for Rani Therapeutics Holdings (RANI) over the last 5 years, with Q3 2025 value amounting to $416305.0.

  • Rani Therapeutics Holdings' Treasury Shares fell 5339.66% to $416305.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $416305.0, marking a year-over-year decrease of 5339.66%. This contributed to the annual value of $811893.0 for FY2024, which is 3637.76% down from last year.
  • According to the latest figures from Q3 2025, Rani Therapeutics Holdings' Treasury Shares is $416305.0, which was down 5339.66% from $485083.0 recorded in Q2 2025.
  • Rani Therapeutics Holdings' Treasury Shares' 5-year high stood at $1.3 million during Q4 2023, with a 5-year trough of $416305.0 in Q3 2025.
  • For the 5-year period, Rani Therapeutics Holdings' Treasury Shares averaged around $753942.1, with its median value being $675575.0 (2022).
  • In the last 5 years, Rani Therapeutics Holdings' Treasury Shares skyrocketed by 9175.22% in 2023 and then tumbled by 5339.66% in 2025.
  • Rani Therapeutics Holdings' Treasury Shares (Quarter) stood at $596500.0 in 2021, then grew by 11.57% to $665500.0 in 2022, then skyrocketed by 91.75% to $1.3 million in 2023, then crashed by 36.38% to $811893.0 in 2024, then plummeted by 48.72% to $416305.0 in 2025.
  • Its Treasury Shares was $416305.0 in Q3 2025, compared to $485083.0 in Q2 2025 and $652869.0 in Q1 2025.